CERo Therapeutics (CERO) said on Monday that it presented preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in preclinical models with no indications of toxicity in animal models.
Shares surged 140% as intraday trading volume soared to more than 1.16 billion from a daily average of about 8.8 million.
RadNet (RDNT) shares soared as Q3 adjusted earnings and revenue reported late Sunday rose more than forecast.
Shares advanced 20% as intraday trading volume climbed to over 1.8 million from a daily average of about 523,000.
Jefferies was one of several brokerage firms to adjust its price target for Bristol-Myers Squibb (BMY). It raised the price target to $63 from $58 while maintaining the hold rating.
Shares of Bristol-Myers jumped 11%, with intraday trading volume at over 18.3 million compared with a daily average of about 10.6 million.
Price: 0.17, Change: +0.10, Percent Change: +140.00
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。